The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling
Open accessAbstract
BACKGROUND: The existing estimate of the global burden of latent TB infection (LTBI) as "one-third" of the world population is nearly 20 y old. Given the importance of controlling LTBI as part of the End TB Strategy for eliminating TB by 2050, changes in demography and scientific understanding, and progress in TB control, it is important to re-assess the global burden of LTBI. METHODS AND FINDINGS: We constructed trends in annual risk in infection (ARI) for countries between 1934 and 2014 using a combination of direct estimates of ARI from LTBI surveys (131 surveys from 1950 to 2011) and indirect estimates of ARI calculated from World Health Organisation (WHO) estimates of smear positive TB prevalence from 1990 to 2014. Gaussian process regression was used to generate ARIs for country-years without data and to represent uncertainty. Estimated ARI time-series were applied to the demography in each country to calculate the number and proportions of individuals infected, recently infected (infected within 2 y), and recently infected with isoniazid (INH)-resistant strains. Resulting estimates were aggregated by WHO region. We estimated the contribution of existing infections to TB incidence in 2035 and 2050. In 2014, the global burden of LTBI was 23.0% (95% uncertainty interval [UI]: 20.4%-26.4%), amounting to approximately 1.7 billion people. WHO South-East Asia, Western-Pacific, and Africa regions had the highest prevalence and accounted for around 80% of those with LTBI. Prevalence of recent infection was 0.8% (95% UI: 0.7%-0.9%) of the global population, amounting to 55.5 (95% UI: 48.2-63.8) million individuals currently at high risk of TB disease, of which 10.9% (95% UI:10.2%-11.8%) was isoniazid-resistant. Current LTBI alone, assuming no additional infections from 2015 onwards, would be expected to generate TB incidences in the region of 16.5 per 100,000 per year in 2035 and 8.3 per 100,000 per year in 2050. Limitations included the quantity and methodological heterogeneity of direct ARI data, and limited evidence to inform on potential clearance of LTBI. CONCLUSIONS: We estimate that approximately 1.7 billion individuals were latently infected with Mycobacterium tuberculosis (M.tb) globally in 2014, just under a quarter of the global population. Investment in new tools to improve diagnosis and treatment of those with LTBI at risk of progressing to disease is urgently needed to address this latent reservoir if the 2050 target of eliminating TB is to be reached.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An estimated 1.7 billion have tuberculosis infections that are “latent.”56”
From Global health 2050: the path to halving premature death by mid-century (2024) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dye, C., Scheele, S., >Dolin, P., Pathania, V. S., Raviglione, M. C., & for the WHO Global Surveillance and Monitoring Project (1999) · JAMA · doi:10.1001/jama.282.7.677 · Cited by 2,955
The Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., & Dye, C. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1009 · Cited by 2,553
Uplekar, M., Weil, D., Lonnroth, K., Jaramillo, E., Lienhardt, C., Dias, H. M., Falzon, D., Floyd, K., Gargioni, G., Getahun, H., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60570-0 · Cited by 1,117
Trunz, B. B., Fine, P., & Dye, C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68507-3 · Cited by 1,114
Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection
Pai, M., Denkinger, C. M., Kik, S. V., Rangaka, M. X., Zwerling, A. A., Oxlade, O., Metcalfe, J. Z., Cattamanchi, A., Dowdy, D. W., Dheda, K. U. J., et al. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00034-13 · Cited by 881
A blood RNA signature for tuberculosis disease risk: a prospective cohort study
Zak, D. E., Penn‐Nicholson, A., Scriba, T. J., Thompson, E. G., Suliman, S., Amon, L. M., Mahomed, H., Erasmus, M., Whatney, W. E., Hussey, G. D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01316-1 · Cited by 779
Latent Mycobacterium tuberculosis Infection
Getahun, H., Matteelli, A., Chaisson, R. E., & Raviglione, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1405427 · Cited by 776
Vynnycky, E., & Fine, P. (1997) · Epidemiology and Infection · doi:10.1017/s0950268897007917 · Cited by 562
Rangaka, M. X., Wilkinson, K. A., Glynn, J. R., Ling, D. I., Menzies, D., Mwansa-Kambafwile, J. R. M., Fielding, K., Wilkinson, R. J., & Pai, M. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70210-9 · Cited by 475
Burden of childhood tuberculosis in 22 high-burden countries: a mathematical modelling study
Dodd, P. J., Gardiner, E., Coghlan, R., & Seddon, J. A. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(14)70245-1 · Cited by 368
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 1,001–1,001 of 1,001
Parwitha, I. A. A., Djunaidy, V. D., Alfian, S. D., Setyowibowo, H., & Pradipta, I. S. (2025) · npj Primary Care Respiratory Medicine · doi:10.1038/s41533-025-00449-3 · Cited by 4
“One major obstacle to achieving the end-TB goal is that 5 – 10% of people with latent tuberculosis infection (LTBI) may progress to TB disease, perpetuating the transmission cycle 2,3 .”
Metadata
- Authors
- Houben, R. M. G. J., & Dodd, P. J.
- Affiliations
- London School of Hygiene & Tropical Medicine (GB)
- University of Sheffield (GB)
- Corresponding author
- Houben, Rein M. G. J.
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-10-25
- Volume
- 13
- Issue
- 10
- Pages
- e1002152
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC5079585
- OpenAlex
- W2533230523
- Cited by
- 2,054
- References
- 26
- Citations by year
- 2026: 160 · 2025: 259 · 2024: 242 · 2023: 243 · 2022: 208 · 2021: 237 · 2020: 257 · 2019: 205 · 2018: 167 · 2017: 67 · 2016: 5
- FWCI
- 22.73
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Bill and Melinda Gates Foundation (US) (OPP1084276)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › HIV, TB, and STIs Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Keywords
- latent tuberculosis infection, global burden of disease, annual risk of infection, isoniazid-resistant tuberculosis, recent infection, End TB Strategy, Gaussian process regression, WHO regions, tuberculosis control, uncertainty quantification, demography
- MeSH terms
- Antitubercular Agents, Humans, Isoniazid, Mycobacterium tuberculosis, Risk, Global Health, Incidence, Prevalence, Tuberculosis, Multidrug-Resistant, Latent Tuberculosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review